• Skip to primary navigation
  • Skip to main content
Rebiotix Logo

Rebiotix

Powerful Therapy Delivered

  • Home
  • About
    • Senior Management
    • Stool Donor Program
    • Careers and Employment
  • Our Therapy
    • The Human Microbiome
    • Microbiota Restoration Therapy
    • Clostridioides difficile Infection
    • The Future of Microbiome-Based Therapeutics
  • Clinical Trials
    • RBX2660 Clinical Trials
    • RBX7455 Clinical Evaluation
    • Physician-sponsored Studies
    • Patient Resources
    • Expanded Access Policy
  • Science
    • Congress Publications
    • Manuscripts and Whitepapers
    • Related Evidence
  • Media
    • Latest Press Releases
    • Frequently Asked Questions
    • “Rebiotix” in the News
    • Conferences
    • Media Tools
    • Presentations & Videos
    • Contacts
  • Contact Us
  • Show Search
Hide Search

Prevention of Recurrent Clostridioides difficile Infection at Two Years After Treatment with Investigational Microbiota-Based Drug RBX2660:  Efficacy, Durability, Microbiome Changes, and Participant Demographics of a Phase 2 Open-Label Clinical Trial  

Christina Reimer MD, PhD1, Robert Orenstein DO2, Lindy Bancke PharmD3, Carlos Gonzalez MS4, Ken Blount PhD3
1Ferring Pharmaceuticals, Copenhagen, Denmark; 2Mayo Clinic in Arizona, Phoenix, AZ; 3Rebiotix Inc, Roseville, MN; 4BioRankings, St. Louis, MO

Download the abstract (26 KB)
Download the poster (2 MB)

World Congress of Gastroenterology @ ACG 2020
October 23-28, 2020, Nashville, TN

Objective

Clostridioides difficile infection (CDI) is a global disease associated with mortality, morbidity, compromised quality of life, and substantial medical cost. Disruption of the intestinal microbiome contributes to recurrent CDI (rCDI), motivating development of microbiota therapies to prevent rCDI in multi-recurrent individuals. We present the 24-month analysis of safety, efficacy, and microbiome restoration from a Phase 2 open-label trial of the investigational microbiota-based drug RBX2660 for prevention of CDI recurrence. To address potential demographic differences on treatment outcome and durability, we also report a subpopulation analysis.  

Methods

This multicenter, open-label Phase 2 trial included participants with multi-recurrent CDI who received <2 doses of RBX2660 delivered via enema 7 days apart.  Efficacy was defined as absence of CDI recurrence through 8 weeks after the last dose. Durability was defined as continued CDI absence beyond 8 weeks. Safety and durability assessments occurred at 3, 6, 12, and 24 months. A general linear model was performed to assess the influence of sex(female, male), age(>65 years, <65 years), and their interaction on clinical outcome. Participant stool samples were collected prior to and for up to 24 months after treatment, and microbiome changes were assessed by shallow shotgun sequencing.

Results

As previously reported, the 8-week efficacy to prevent rCDI (79%;112/142) was higher than the CDI-free rate in the historical control group (31%, 23/75; p<.0001). Ninety-seven participants who achieved treatment success at 8 weeks were evaluable for long-term durability of whom 8 experienced a new CDI episode between 8 weeks and 24-months (92% overall durability). Age and sex did not have a statistically significant impact on primary efficacy or durability. The safety profile of RBX2660 was acceptable up to 24 months and consistent with prior reports of microbiota-directed treatments; gastrointestinal disorders were the most common TEAE organ class. Microbiome analysis (503 samples from 110 primary treatment responders) showed that the relative abundance of Bacteroidia and Clostridia increased significantly within 7 days of treatment relative to baseline, concomitant with a decrease of Gammaproteobacteria and Bacilli, with maintenance of these changes throughout 24 months.

Conclusions

The microbiota-based drug RBX2660 demonstrated clinical durability in preventing rCDI at 24 months.  This maintained efficacy was associated with sustained shifts in microbiome composition following treatment. Importantly, neither efficacy nor durability was dependent on age or sex.

Microbiota Restoration Therapy Abstracts, Microbiota Restoration Therapy Posters Abstracts, Posters

Interested in Becoming a Stool Donor? Learn More

Rebiotix

  • Copyright © 2022 Rebiotix, Inc.
  • A Ferring Company
  • Privacy Policy
  • Terms of Use
  • Sitemap
  • Contact Us

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT